I assume distribution. Hard to value a 1-approved-drug bio company with a not-yet-commercialized cure for a self-described 'rare condition' at 13B .
Also usually when things go up a lot they come down a bit first?
Also usually when things go up a lot they come down a bit first?
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。